118 related articles for article (PubMed ID: 29467873)
1. Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia.
Kushitani K; Amatya VJ; Mawas AS; Suzuki R; Miyata Y; Okada M; Inai K; Kishimoto T; Takeshima Y
Oncol Lett; 2018 Mar; 15(3):3540-3547. PubMed ID: 29467873
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic Utility of BAP1, EZH2 and Survivin in Differentiating Pleural Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia: Immunohistochemical Study.
Hakim SA; Abou Gabal HH
Pathol Oncol Res; 2021; 27():600073. PubMed ID: 34257556
[No Abstract] [Full Text] [Related]
3. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Iwasaki A; Nabeshima K
Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.
Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
Lung Cancer; 2017 Feb; 104():98-105. PubMed ID: 28213009
[TBL] [Abstract][Full Text] [Related]
5. 5-hmC loss is another useful tool in addition to BAP1 and MTAP immunostains to distinguish diffuse malignant peritoneal mesothelioma from reactive mesothelial hyperplasia in peritoneal cytology cell-blocks and biopsies.
Alsugair Z; Kepenekian V; Fenouil T; Glehen O; Villeneuve L; Isaac S; Hommell-Fontaine J; Benzerdjeb N
Virchows Arch; 2022 Jul; 481(1):23-29. PubMed ID: 35575935
[TBL] [Abstract][Full Text] [Related]
6. BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests.
Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
Pathol Int; 2016 Oct; 66(10):563-570. PubMed ID: 27614970
[TBL] [Abstract][Full Text] [Related]
7. Use of Anti-Noxa Antibody for Differential Diagnosis between Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia.
Kushitani K; Amatya VJ; Mawas AS; Miyata Y; Okada M; Takeshima Y
Pathobiology; 2016; 83(1):33-40. PubMed ID: 26735863
[TBL] [Abstract][Full Text] [Related]
8. Can BAP1 expression loss in mesothelial cells be an indicator of malignancy?
Ozdemir HG; Kokten SC; Barisik NO
J Pathol Transl Med; 2020 Nov; 54(6):497-503. PubMed ID: 33153245
[TBL] [Abstract][Full Text] [Related]
9. [Expression of glucose transporter protein 1 and desmin in reactive mesothelial hyperplasia and epithelioid malignant mesothelioma].
Wei P; Jin ML; Zhao HY; Li X; Diao XL
Zhonghua Bing Li Xue Za Zhi; 2013 Jul; 42(7):451-4. PubMed ID: 24246863
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic accuracy of BRCA1-associated protein 1 in malignant mesothelioma: a meta-analysis.
Wang LM; Shi ZW; Wang JL; Lv Z; Du FB; Yang QB; Wang Y
Oncotarget; 2017 Sep; 8(40):68863-68872. PubMed ID: 28978163
[TBL] [Abstract][Full Text] [Related]
11. A gene-expression-based test can outperform bap1 and
Alì G; Bruno R; Poma AM; Proietti A; Ricci S; Chella A; Melfi F; Ambrogi MC; Lucchi M; Fontanini G
Oncol Lett; 2020 Jan; 19(1):1060-1065. PubMed ID: 31897219
[TBL] [Abstract][Full Text] [Related]
12. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
13. Loss of BRCA1-associated protein 1 (BAP1) expression is rare in non-small cell lung cancer.
Owen D; Sheffield BS; Ionescu D; Churg A
Hum Pathol; 2017 Feb; 60():82-85. PubMed ID: 27984124
[TBL] [Abstract][Full Text] [Related]
14. Cell proliferation rate and telomerase activity in the differential diagnosis between benign and malignant mesothelial proliferations.
Cakir C; Gulluoglu MG; Yilmazbayhan D
Pathology; 2006 Feb; 38(1):10-5. PubMed ID: 16484001
[TBL] [Abstract][Full Text] [Related]
15. [BRCA1 associated protein 1 (BAP1) expression in pleural diffuse malignant mesothelioma: A comparative cytological and histological analyses on 50 patients].
Jaouen A; Thivolet-Bejui F; Chalabreysse L; Piaton E; Traverse-Glehen A; Isaac S; Decaussin-Petrucci M; Depaepe L; Fontaine J; Remy I; Maury JM; Brevet M
Ann Pathol; 2016 Apr; 36(2):111-9. PubMed ID: 26995100
[TBL] [Abstract][Full Text] [Related]
16. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections.
Mayall FG; Goddard H; Gibbs AR
J Pathol; 1992 Dec; 168(4):377-81. PubMed ID: 1484319
[TBL] [Abstract][Full Text] [Related]
17. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
Cury PM; Butcher DN; Corrin B; Nicholson AG
J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
[TBL] [Abstract][Full Text] [Related]
18. Utility of BRCA1-associated protein 1 immunoperoxidase stain to differentiate benign versus malignant mesothelial proliferations in cytologic specimens.
McCroskey Z; Staerkel G; Roy-Chowdhuri S
Diagn Cytopathol; 2017 Apr; 45(4):312-319. PubMed ID: 28205427
[TBL] [Abstract][Full Text] [Related]
19. Loss of expression of BAP1 predicts longer survival in mesothelioma.
Farzin M; Toon CW; Clarkson A; Sioson L; Watson N; Andrici J; Gill AJ
Pathology; 2015 Jun; 47(4):302-7. PubMed ID: 25938359
[TBL] [Abstract][Full Text] [Related]
20. Differential diagnosis of reactive mesothelial cells and malignant mesothelioma cells using the cell proliferation markers minichromosome maintenance protein 7, geminin, topoisomerase II alpha and Ki-67.
Kimura F; Okayasu I; Kakinuma H; Satoh Y; Kuwao S; Saegusa M; Watanabe J
Acta Cytol; 2013; 57(4):384-90. PubMed ID: 23860238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]